Control of the heparosan N-deacetylation leads to an improved bioengineered heparin
- 12 April 2011
- journal article
- research article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 91 (1) , 91-99
Abstract
The production of the anticoagulant drug heparin from non-animal sources has a number of advantages over the current commercial production of heparin. These advantages include better source material availability, improved quality control, and reduced concerns about animal virus or prion impurities. A bioengineered heparin would have to be chemically and biologically equivalent to be substituted for animal-sourced heparin as a pharmaceutical. In an effort to produce bioengineered heparin that more closely resembles pharmaceutical heparin, we have investigated a key step in the process involving the N-deacetylation of heparosan. The extent of N-deacetylation directly affects the N-acetyl/N-sulfo ratio in bioengineered heparin and also impacts its molecular weight. Previous studies have demonstrated that the presence and quantity of N-acetylglucosamine in the nascent glycosaminoglycan chain, serving as the substrate for the subsequent enzymatic modifications (C5 epimerization and O-sulfonation), can impact the action of these enzymes and, thus, the content and distribution of iduronic acid and O-sulfo groups. In this study, we control the N-deacetylation of heparosan to produce a bioengineered heparin with an N-acetyl/N-sulfo ratio and molecular weight that is similar to animal-sourced pharmaceutical heparin. The structural composition and anticoagulant activity of the resultant bioengineered heparin was extensively characterized and compared to pharmaceutical heparin obtained from porcine intestinal mucosa.Keywords
This publication has 30 references indexed in Scilit:
- E. coli K5 fermentation and the preparation of heparosan, a bioengineered heparin precursorBiotechnology and Bioengineering, 2010
- Analysis of E. coli K5 capsular polysaccharide heparosanAnalytical and Bioanalytical Chemistry, 2010
- Lessons learned from the contamination of heparinNatural Product Reports, 2009
- Solution Structures of Chemoenzymatically Synthesized Heparin and Its PrecursorsJournal of the American Chemical Society, 2008
- Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical eventsNature Biotechnology, 2008
- Ultraperformance Ion-Pair Liquid Chromatography Coupled to Electrospray Time-of-Flight Mass Spectrometry for Compositional Profiling and Quantification of Heparin and Heparan SulfateAnalytical Chemistry, 2008
- Using an Enzymatic Combinatorial Approach to Identify Anticoagulant Heparan Sulfate StructuresChemistry & Biology, 2007
- Heparin-Binding Domains in Vascular BiologyArteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Combined Quantitative 1H and 13C Nuclear Magnetic Resonance Spectroscopy for Characterization of Heparin PreparationsSeminars in Thrombosis and Hemostasis, 2001
- The Effect of Precursor Structures on the Action of Glucosaminyl 3-O-Sulfotransferase-1 and the Biosynthesis of Anticoagulant Heparan SulfateJournal of Biological Chemistry, 2001